Fukai Ryuta, Sakao Yukinori, Sakuraba Motoki, Oh Shiaki, Shiomi Kazu, Sonobe Satoshi, Saitoh Yuichi, Miyamoto Hideaki
Department of General Thoracic Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan.
Eur J Cardiothorac Surg. 2007 Sep;32(3):440-4. doi: 10.1016/j.ejcts.2007.06.011. Epub 2007 Jul 23.
To evaluate the significance of preoperative clinicopathological factors, including serum carcinoembryonic antigen (CEA), as well as postoperative clinicopathological factors in T1-2N1M0 patients with non-small cell lung cancer who underwent curative pulmonary resection.
Twenty T1N1M0 disease patients and 25 T2N1M0 patients underwent standard surgical procedures between September 1996 and December 2005, and were found to have non-small lung cancer. As prognostic factors, we retrospectively investigated age, sex, Brinkman index, histologic type, primary site, tumor diameter, clinical T factor, clinical N factor, pathological T factor, preoperative serum CEA levels, surgical procedure, visceral pleural involvement, and the status of lymph node involvement (level and number).
The overall 5-year survival rate of all patients was 59.6%. In univariate analysis, survival was related to age (<70/>or=70 years, p=0.0079), site (peripheral/central, p=0.043), and CEA level (<5.0/>or=5.0 ng/ml, p=0.0015). However, in multivariate analysis, CEA (<5.0/>or=5.0 ng/ml) was the only independent prognostic factor; the 5-year survival of the patients with an elevated serum CEA level (>or=5.0 ng/ml) was only 33.2% compared to 79.9% in patients with a lower serum CEA level (<5.0 ng/ml).
An elevated serum CEA level (>or=5.0 ng/ml) was an independent predictor of survival in pN1 patients except for T3 and T4 cases. Therefore, even in completely resected pN1 non-small cell lung cancer, patients with a high CEA level might be candidates for multimodal therapy.
评估术前临床病理因素(包括血清癌胚抗原(CEA))以及术后临床病理因素在接受根治性肺切除的T1-2N1M0非小细胞肺癌患者中的意义。
1996年9月至2005年12月期间,20例T1N1M0疾病患者和25例T2N1M0患者接受了标准手术程序,被诊断为非小细胞肺癌。作为预后因素,我们回顾性研究了年龄、性别、布林克曼指数、组织学类型、原发部位、肿瘤直径、临床T因子、临床N因子、病理T因子、术前血清CEA水平、手术程序、脏层胸膜受累情况以及淋巴结受累状态(水平和数量)。
所有患者的总体5年生存率为59.6%。单因素分析中,生存与年龄(<70岁/≥70岁,p=0.0079)、部位(外周/中央,p=0.043)和CEA水平(<5.0/≥5.0 ng/ml,p=0.0015)有关。然而,多因素分析中,CEA(<5.0/≥5.0 ng/ml)是唯一的独立预后因素;血清CEA水平升高(≥5.0 ng/ml)的患者5年生存率仅为33.2%,而血清CEA水平较低(<5.0 ng/ml)的患者为79.9%。
血清CEA水平升高(≥5.0 ng/ml)是除T3和T4病例外pN1患者生存的独立预测因素。因此,即使在完全切除的pN1非小细胞肺癌中,CEA水平高的患者也可能是多模式治疗的候选者。